DailyStocks Stock Article Search

https://www.zacks.com/stock/news/2258650/vertex-vrtx-begins-rolling-nda-filing-for-acute-pain-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2258650 Apr 19, 2024 - Vertex (VRTX) begins rolling NDA submission for its investigational non-opioid candidate, suzetrigine, for acute pain management. The submission is expected to be completed in second-quarter 2024. 0

https://www.zacks.com/stock/news/2257798/diamedica-dmac-up-as-stroke-study-dosing-begins-post-relaunch?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2257798 Apr 18, 2024 - DiaMedica (DMAC) rises 10% as it doses the first patient in the relaunch of its pivotal study evaluating the lead candidate, DM199, to treat acute ischemic stroke. 0

https://www.zacks.com/stock/news/2254517/is-entera-bio-entx-outperforming-other-medical-stocks-this-year?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_1-2254517 Apr 12, 2024 - Here is how Entera Bio Ltd. (ENTX) and FibroGen (FGEN) have performed compared to their sector so far this year. 0

https://www.zacks.com/stock/news/2251543/aldeyra-aldx-stock-rallies-43-in-one-week-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2251543 Apr 06, 2024 - Aldeyra (ALDX) rises 43% in one week, driven by plans to initiate a pivotal study to support the resubmission of reproxalap NDA for dry eye disease in the first half of 2024. 0

https://www.zacks.com/stock/news/2249898/evaxion-evax-up-on-upbeat-preclinical-s-aureus-vaccine-data?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249898 Apr 03, 2024 - Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection. 0

https://www.zacks.com/stock/news/2241321/mirum-s-mirm-livmarli-receives-fda-nod-for-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241321 Mar 15, 2024 - Mirum's (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC. 0

https://www.zacks.com/stock/news/2240793/astrazeneca-azn-to-acquire-amolyt-pharma-for-1-05-billion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240793 Mar 14, 2024 - AstraZeneca (AZN) enters into an agreement to acquire Amolyt Pharma to strengthen its rare disease pipeline by adding the latter's late-stage hypoparathyroidism treatment candidate, eneboparatide. 0

https://www.zacks.com/stock/news/2239502/regeneron-regn-gets-fda-nod-for-praluent-label-extension?cid=CS-ZC-FT-analyst_blog|earnings_article-2239502 Mar 12, 2024 - Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH. 0

https://seekingalpha.com/article/4673627-fibrogen-inc-fgen-q4-2023-earnings-call-transcript?source=feed_sector_transcripts Feb 26, 2024 - FibroGen, Inc. (NASDAQ:NASDAQ:FGEN) Q4 2023 Earnings Conference Call February 26, 2024 5:00 PM ETCompany ParticipantsDavid DeLucia - Head of Corporate... 0